Annotation of rs5326

Genotypes CT + TT are associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC.

Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002). Please note that alleles have been complemented to the plus chromosomal strand.

From Publication

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. The pharmacogenomics journal. 2014. McCracken J T et al.
PMID:23856854(opens in new window) PMCID:PMC4034115(opens in new window) DOI:10.1038/tpj.2013.23(opens in new window)

Gene

DRD1

Variant

rs5326

Phenotype Category

Efficacy

Association Significance

The study reports this association is significant

Specialty Population

PediatricLearn more about pediatric tags(opens in new window)

PharmGKB ID

1184510511

Score
More info on scoring

2.25

Evidence for Clinical Annotations

This annotation has not been used as evidence for any clinical annotations.

Study Parameters

Study type

cohort

Study size

58

Association p-value

= 0.006

Biogeographical group
More info on groups

Multiple groups

Population description

children (pediatrics)

Disease: Autistic disorder, Asperger's disorder or pervasive developmental disorder.

Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

History

No history available.